Previous 10 | Next 10 |
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q3 2021 Earnings Call Nov 04, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q3 2021 Earnings Call Transcript ...
Global Blood Therapeutics, Inc. (NASDAQ:GBT) Q3 2021 Earnings Conference Call November 04, 2021, 4:30 PM ET Company Participants Ted Love - President and CEO Jeff Farrow - Chief Financial Officer David Johnson - Chief Commercial Officer Kim Smith-Whitley - EVP and Head of R&D Steven Immer...
Global Blood Therapeutics (NASDAQ:GBT): Q3 GAAP EPS of -$1.13 misses by $0.02. Revenue of $52.05M (+41.1% Y/Y) misses by $1.64M. Press Release Cash, cash equivalents, and marketable securities totaled $416.8 million at September 30, 2021, compared with $560.9 million ...
Achieved Oxbryta ® (voxelotor) net revenues of $52.1 million, a 41% increase year over year Oxbryta sNDA and NDA for pediatric label expansion accepted by FDA for priority review; PDUFA target action date of December 25, 2021 Conference call today at 4:30 ...
Accepted Abstracts Include Real-World Experience with Oxbryta ® (voxelotor) and Phase 1 Data on GBT021601 and Inclacumab SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that six abstract...
Considered the equivalent of the Nobel Prize in biopharmaceutical research, Prix Galien USA honors Oxbryta as the Best Biotechnology Product for 2021 Oxbryta is the first and only approved therapy that directly inhibits the root cause of the sickling and destruction of red blood...
Company to also host R&D Day on Thursday, November 11 in New York City and via video webcast SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report third quarter 2021 financi...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Cantor Global Healthcare Conference on Monday, September 27, 2021, at 2:40 p.m. ET. T...
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the launch of The GBT Foundation, a 501(c)(3) organization and source of charitable giving that will work to improve the health and well-being of underserve...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...